StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy ...

A downtrend has been apparent in Supernus Pharmaceuticals (SUPN) lately with too much selling pressure. The stock has declined 20.1% over the past four weeks. However, given the fact that it is now in ...

Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN). The branded pharmaceutical industry relies on a high-cost, high-reward business model, ...

ROCKVILLE, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been ...

Swiss National Bank lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 0.7% in the fourth ...

Highlights,Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals, reflecting growing institutional activity.,Several financial firms, including Janney Montgomery Scott LLC and ...

Ritz-Carlton South Beach, Miami, Fla. Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinators.

Supernus (SUPN) announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of ...

About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS ...